Why aren't depot antipsychotics prescribed more often and what can be done about it?

Advances in Psychiatric Treatment

Volumn 11, Issue 3, 2005, Pages 203-213

  Patel, Maxine X ^a   David, Anthony S ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

DRUG FORMULATION; DRUG INDICATION; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE SYSTEM; HUMAN; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MENTAL HEALTH SERVICE; NURSE ATTITUDE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIST; PUBLIC OPINION; RELAPSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT PLANNING;

EID: 18844378365     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.11.3.203     Document Type: Review

References (50)

1. Adams, C. E., Fenton, M. K. P., Quraishi, S., et al (2001) Systemic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry, 179, 290-299.
2. Altamura, A. C., Sassella, F., Santini, A., et al (2003) Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs, 63, 495-512.
3. Anderson, D., Leadbetter, A. & Williams, B. (1989) In defence of the depot clinic: the consumer's opinion. Psychiatric Bulletin, 13, 177-179.
4. Awad, A. G. (1993) Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin, 19, 609-618.
5. Bains, J. J. S. & Neilssen, O. B. (2003) Combining depot antipsychotic medications with novel antipsychotics in forensic patients: a practice in search of a principle. Psychiatric Bulletin, 27, 14-16.
6. Baldessarini, R. J., Cohen, B. M. & Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79-91.
7. Barnes, T. R. & Curson, D. A. (1994) Long-term depot antipsychotics. A risk-benefit assessment. Drug Safety, 10, 464-479.
8. Bennett, J., Done, J. & Hunt, B. (1995) Assessing the side-effects of antipsychotic drugs: a survey of CPN practice. Journal of Psychiatric and Mental Health Nursing, 2, 177-182.
9. Carpenter, W. T., Jr., Buchanan, R. W., Kirkpatrick, B., et al (1999) Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. American Journal of Psychiatry, 156, 412-418.
10. Cramer, J. A. & Rosenheck, R. (1998) Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49, 196-201.
11. Curson, D. A., Barnes, T. R., Bamber, R. W., et al (1985) Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. British Journal of Psychiatry, 146, 469-474.
12. Darby, J. K., Pasta, D. J., Dabiri, L., et al (1995) Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. Journal of Clinical Psychopharmacology, 15, 334-340.
13. Davis, J. M., Matalon, L., Watanabe, M. D., et al (1994) Depot antipsychotic drugs. Place in therapy. Drugs, 47, 741-773.
14. Dencker, S. J. & Axelsson, R. (1996) Optimising the use of depot antipsychotics. CNS Drugs, 6, 367-381.
15. Fleischhacker, W. W., Eerdekens, M., Karcher, K., et al (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry, 64, 1250-1257.
16. Gerlach, J. (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages. International Clinical Psychopharmacology, 9 (suppl. 5), 17-20.
17. Glazer, W. M. & Kane, J. M. (1992) Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry, 53, 426-433.
18. Hoencamp, E., Knegtering, H., Kooy, J. J., et al (1995) Patient requests and attitude towards neuroleptics. Nordic Journal of Psychiatry, 49 (suppl. 35), 47-55.
19. Hogan, T. P., Awad, A. G. & Eastwood, R. (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine, 13, 177-183.
20. Hughes, I., Hill, B. & Budd, R. (1997) Compliance with antipsychotic medication: from theory to practice. Journal of Mental Health, 6, 473-489.
21. Kane, J. M., Aguglia, E., Altamura, A. C., et al (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology, 8, 55-66.
22. Kane, J. M., Eerdekens, M., Lindenmayer, J.-P., et al (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry, 160, 1125-1132.
23. Kemp, R., Kirov, G., Everitt, B., et al (1998) Randomised controlled trial of compliance therapy: 18-month follow-up. British Journal of Psychiatry, 172, 413-419.
24. Kendrick, T., Millar, E., Burns, T., et al (1998) Practice nurse involvement in giving depot neuroleptic injections. Development of a patient assessment and monitoring checklist. Primary Care Psychiatry, 4, 149-154.
25. Kissling, W. (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scandinavica Supplementum, 382, 16-24.
26. Kissling, W. (1997) Compliance, quality management and standards in the treatment of schizophrenia. Neuropsychobiology, 35, 70-72.
27. Lambert, T., Brennan, A., Castle, D., et al (2003) Perception of depot antipsychotics by mental health professionals. Journal of Psychiatric Practice, 9, 252-260.
28. Lindstrom, E. & Bingefors, K. (2000) Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics, 18, 106-124.
29. Marland, G. R. & Sharkey, V. (1999) Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. Journal of Advanced Nursing, 30, 1255-1262.
30. National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43. London: NICE. http://www.nice.org.uk/pdf/ANTIPSYCHOTICfinalguidance.pdf.
31. O'Ceallaigh, S. & Fahy, T. (2001) Is there a role for the depot clinic in the modern management of schizophrenia? Psychiatric Bulletin, 25, 481-484.
32. Patel, M. X. & David, A. S. (2004) Medication adherence: predictive factors and enhancement strategies. Psychiatry, 3 (10), 41-44.
33. Patel, M. X., Nikolaou, V. & David, A. S. (2003a) Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychological Medicine, 33, 83-89.
34. Patel, M. X., Nikolaou, V. & David, A. S. (2003b) Eliciting psychiatrists' beliefs about side-effects of typical and atypical antipsychotic drugs. International Journal of Psychiatry in Clinical Practice, 7, 117-120.
35. Patel, M. X., deZoysa, N., Baker, D., et al (2005) Depot antipsychotic medication and attitudes of community psychiatric nurses. Journal of Psychiatric and Mental Health Nursing, 12, 237-244.
36. Pereira, S. & Pinto, R. (1997) A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatrica Scandinavica, 95, 464-468.
37. Remington, G. J. & Adams, M. E. (1995) Depot neuroleptic therapy: clinical considerations. Canadian Journal of Psychiatry, 40 (suppl. 1), S5-S11.
38. Royal College of Nursing (1994) Good Practice in the Administration of Depot Injections. London: Department of Health /Royal College of Nursing.
39. Smith, J. A., Hughes, I. C. T. & Budd, R. J. (1999) Noncompliance with antipsychotic medication. User's views on advantages and disadvantages. Journal of Mental Health, 8, 287-296.
40. Svedberg, B., Backenroth-Ohsako, G. & Lutzen, K. (2003) On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. International Journal of Mental Health Nursing, 12, 110-118.
41. Tavcar, R., Dernovsek, M. Z. & Zvan, V. (2000) Choosing antipsychotic maintenance therapy - a naturalistic study. Pharmacopsychiatry, 33, 66-71.
42. Taylor, D., Mir, S., Mace, S., et al (1999) Is Cost a Factor? A Survey of Psychiatrists and Health Authorities to Determine the Factors Influencing the Prescribing and Funding of Atypical Antipsychotics. London: National Schizophrenia Fellowship.
43. Valenstein, M., Copeland, L. A., Owen, R., et al (2001) Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Journal of Clinical Psychiatry, 62, 545-551.
44. Walburn, J., Gray, R., Gournay, K., et al (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry, 179, 300-307.
45. Weiden, P. & Glazer, W. (1997) Assessment and treatment selection for 'revolving door' inpatients with schizophrenia. Psychiatric Quarterly, 68, 377-392.
46. Weiden, P., Rapkin, B., Mott, T., et al (1994) Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin, 20, 297-310.
47. Wistedt, B. (1995) How does the psychiatric patient feel about depot treatment, compulsion or help? Nordic Journal of Psychiatry, 49 (suppl. 35), 41-46.
48. Young, J. L., Zonana, H. V. & Shepler, L. (1986) Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law, 14, 105-122.
49. Young, J. L., Spitz, R. T., Hillbrand, M., et al (1999) Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments and prospects. Journal of the American Academy of Psychiatry and the Law, 27, 426-444.
50. Zygmunt, A., Olfson, M., Boyer, C. A., et al (2002) Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry, 159, 1653-1664.